Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Free Eye Drops Distribution To Mitigate Drug Side Effects Cleared By HHS OIG

Executive Summary

Program relies on a third-party vendor managing a Risk Evaluation and Mitigation Strategy associated with the drug to facilitate delivery of eye drops to patients.

You may also be interested in...



Long-Acting Antipsychotic Sampling Program In Hospitals Cleared By OIG Advisory Opinion

Sample program focuses only on inpatient use and in hospitals that do not accept Prescription Drug Marketing Act-compliant trial units. By improving adherence, program could lower federal health care costs over time, Office of Inspector General suggests.

Novartis CAR-T Patient Assistance Program Could Set Template For Other One-Time Treatments

HHS gives kickback exemption for program to provide Kymriah for free to certain eligible patients regardless of insurance provider. Treatment’s one-time use as a last resort therapy were key to the US government’s advisory opinion reasoning.

GSK’s Blenrep Wins BCMA Race, Carries Ocular Toxicity Warning

US FDA-approved belantamab mafodotin is indicated for heavily pre-treated multiple myeloma and has a list price of $23,900 per month. Its REMS could limit initial uptake, but response rates have been encouraging.

Topics

Related Companies

UsernamePublicRestriction

Register

PS145372

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel